Adebrelimab
- Generic Name
- Adebrelimab
- Drug Type
- Biotech
- CAS Number
- 2247114-85-6
- Unique Ingredient Identifier
- 1XBY50W1OX
- Background
Adebrelimab is under investigation in clinical trial NCT03711305 (Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-stage (ES) Small Cell Lung Cancer (SCLC)).
- Indication
用于与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。
Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors
- First Posted Date
- 2025-01-08
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT06764368
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
Phase 1
Recruiting
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT06754930
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma
Phase 2
Recruiting
- Conditions
- Unresectable Biliary Tract Carcinoma
- Interventions
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 63
- Registration Number
- NCT06749730
- Locations
- 🇨🇳
HeNan, Zhengzhou, China
HAI or IV of Adebrelimab, Combined with Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
Phase 2
Recruiting
- Conditions
- Advanced Hepatocellular Carcinoma (HCC)
- Interventions
- Procedure: HAI AdebrelimabDrug: intravenous infusion (IV) of Adebrelimab (ADE)Drug: intravenous infusion (IV) of Bevacizumab (Bev.)Procedure: HAIC with FOLFOX regimen
- First Posted Date
- 2024-12-17
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 78
- Registration Number
- NCT06737913
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer
Early Phase 1
Not yet recruiting
- Conditions
- NSCLC
- Interventions
- Drug: mRNA Neoantigen Vaccine
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06735508
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2024-11-25
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 876
- Registration Number
- NCT06703177
- Locations
- 🇨🇳
Sun Yat-Sen university cancer center, Guangzhou, Guangdong, China
Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis
Phase 2
Active, not recruiting
- Conditions
- Unresectable Locally Advanced Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Wei Zhou
- Target Recruit Count
- 32
- Registration Number
- NCT06700421
- Locations
- 🇨🇳
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.
Phase 1
Not yet recruiting
- Conditions
- OsteosarcomaSoft Tissue Sarcoma (STS)
- Interventions
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Hansoh BioMedical R&D Company
- Target Recruit Count
- 448
- Registration Number
- NCT06699576
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
Phase 2
Not yet recruiting
- Conditions
- Rare Tumour
- Interventions
- Drug: Other
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Peking University Shenzhen Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06692491
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC
Phase 2
Not yet recruiting
- Conditions
- GC/GEJC
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-12
- Target Recruit Count
- 70
- Registration Number
- NCT06684158
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath